Multi-dimensional recovery trajectories in cannabis-induced psychosis: A systematic review examining symptomatic, functional, cognitive, and subjective outcomes.
Valerio Ricci, Alessandro Sarni, Marialuigia Barresi, Lorenzo Remondino, Giuseppe Maina
Asian Journal of Psychiatry April 1, 2026 DOI: 10.1016/j.ajp.2026.104975 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Longitudinal Peer reviewed |
|---|---|
| Sample size | 18,117 |
| Population | People with cannabis-induced or cannabis-associated first-episode psychosis, followed for at least 6 months |
| Duration | Mean follow-up 24 months (range 6 months to 10 years) |
| Topics | Cannabis |
| Key findings | Symptomatic remission is common (50-70% within six months), but functional recovery is heterogeneous and frequently dissociated from symptom improvement. Continued cannabis use predicts poorer outcomes across domains (persistence rates 35-65%), while cessation is associated with better functional recovery (effect size 1.26). The authors conclude that the "favorable prognosis" narrative inadequately captures multi-dimensional recovery. |
Abstract
Background: Cannabis-induced psychotic disorders represent 12-35% of first-episode psychosis presentations globally. Traditional clinical wisdom holds these conditions carry favorable prognosis based on rapid symptomatic improvement, yet this narrative rests almost exclusively on symptomatic outcomes, overlooking functional, cognitive, and subjective recovery dimensions.
Objective: To systematically review multi-dimensional recovery trajectories following cannabis-induced or cannabis-associated first-episode psychosis, characterizing patterns of concordance and discordance across outcome domains and identifying predictors of recovery profiles.
Methods: We searched five databases (PubMed/MEDLINE, PsycINFO, Embase, Web of Science, Cochrane Library) from inception to December 2024. INCLUSION CRITERIA longitudinal studies (≥6 months follow-up) assessing ≥ 2 outcome domains among symptomatic, functional, cognitive, and subjective recovery in cannabis-induced first-episode psychosis. Two independent reviewers screened studies and assessed quality using Newcastle-Ottawa Scale. Data were synthesized narratively.
Results: Thirty-three studies encompassing 18,117 participants were included (mean follow-up 24 months, range 6 months-10 years). While 50-70% achieved symptomatic remission within 6 months, functional recovery revealed substantial heterogeneity and frequent symptom-function dissociation. Continued cannabis use emerged as strongest predictor of poor outcomes across domains (persistence rates 35-65%), though cessation demonstrated significant benefits (functional recovery effect size 1.26). Cognitive findings were heterogeneous, and subjective outcomes remained poorly characterized (assessed in only 38% of studies). Only 15% of studies employed person-centered trajectory modeling, revealing five distinct recovery profiles.
Conclusions: Symptomatic improvement frequently fails to translate into functional recovery following cannabis-induced psychosis. The field's understanding of "favorable prognosis" inadequately captures comprehensive multi-dimensional recovery, necessitating interventions targeting functional, cognitive, and subjective domains beyond symptomatic remission.
Comparable studies
Other systematic reviews and meta-analyses on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Effects of cannabis use on outcomes of psychotic disorders: systematic review People with psychotic disorders, as examined in 13 longitudinal studies | 2008 | Systematic review | |
| The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample Patients with established schizophrenia (meta-analysis: 572) and patients with... | 2010 | Meta-analysis and cross-sectional observational study | n = 700 |
| Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review | 2020 | Systematic review | |
| Neuroimaging in cannabis use: a systematic review of the literature Cannabis users and controls in neuroimaging studies | 2009 | Systematic review | |
| Human Laboratory Studies on Cannabinoids and Psychosis. Healthy human subjects and individuals with schizophrenia | 2016 | Systematic review |
Citations in the library
Cites 14
- Effects of cannabis use on outcomes of psychotic disorders: systematic review The British Journal of Psychiatry October 31, 2008
- Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases The British Journal of Psychiatry November 30, 2005
- The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample Schizophrenia Bulletin July 25, 2010
- Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals EClinicalMedicine September 8, 2023
- Cannabis and suicide risk in first-episode psychosis: Mechanisms, interactions, and intervention strategies. Asian Journal of Psychiatry July 10, 2025
and 9 more in the library